Last year the biotech company Vaxart (NASDAQ:VXRT) had seen its stock soar by 1500% but the stock eventually cooled down. At this point, the company is focused on its COVID 19 oral pill vaccine and it is believed that in the middle of 2021, the second phase of development might commence.
It can be said that the company has fallen way behind its peers with regards to its vaccine, but it should be noted that Vaxart could still manage to deliver some value.
The most important thing to remember is that a vaccine in the form of a pill might prove to be highly popular for many. In addition to that, if the pill proves to be effective then it could change the minds of those who oppose vaccine jabs. Vaxart had actually commissioned a study in this regard and the poll found that as many as 19 million American could be willing to go for a pill if it became available.